Results 91 to 100 of about 866,592 (283)

Optical Wireless Data and Power Transfer for In‐Body Electronic Devices: A Proof‐of‐Concept Study Using Ex Vivo Porcine Samples

open access: yesIET Optoelectronics
This study presents a proof‐of‐concept system for the joint wireless transfer of data and power to in‐body electronic devices (IEDs) using near‐infrared (NIR) light technology.
Syifaul Fuada   +2 more
doaj   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

A Dilated CNN‐Based Model for Stress Detection Using Raw PPG Signals

open access: yesIET Wireless Sensor Systems
Stress, a common response to challenging situations, has become pervasive in contemporary daily life due to various factors. Persistent stress can weaken the human immune system, increasing the risk of chronic stress and contributing to a range of ...
Koorosh Motaman   +3 more
doaj   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

open access: yesMolecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala   +15 more
wiley   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

supDQN: Supervised Rewarding Strategy Driven Deep Q-Network for sEMG Signal Decontamination

open access: yesIEEE Access
The presence of muscles throughout the active parts of the body, such as the upper and lower limbs, makes electromyography-based human-machine interaction prevalent.
Ashutosh Jena   +4 more
doaj   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

open access: yesMolecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal   +4 more
wiley   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

open access: yesMolecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

An investigation of planar array system artefacts generated within an electrical impedance mammography system developed for breast cancer detection [PDF]

open access: yes, 2014
An Electrical Impedance Mammography (EIM) planar array imaging system is being developed at the University of Sussex for the detection of breast cancers.
Bilal, Rabia   +3 more
core  

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

open access: yesMolecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy